How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia

British Journal of Haematology

Volumn 166, Issue 1, 2014, Pages 3-11

  Ross, David M ^a,b,c   Hughes, Timothy P ^a,b,d  

^a SA Pathology   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

BCR ABL1; Chronic myeloid leukaemia; Minimal residual disease; Treatment free remission; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB; INTERFERON;

AGE; ARTICLE; BCR ABL1 GENE; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG COST; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE EXPRESSION; HUMAN; LEUKEMIA REMISSION; LIFE EXPECTANCY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT FREE REMISSION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

BCR-ABL1; CHRONIC MYELOID LEUKAEMIA; MINIMAL RESIDUAL DISEASE; TREATMENT-FREE REMISSION; TYROSINE KINASE INHIBITORS;

ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; PATIENT SELECTION; PROGNOSIS; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION; WITHHOLDING TREATMENT;

EID: 84902304839     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12892     Document Type: Article

References (54)

1. Alikian, M., Ellery, P., Forbes, M., Gerrard, G., Aitman, T., Kasperaviciute, D., Milojkovic, D., Marin, D., Goldman, J.M., Apperley, J.F., Foroni, L. & Reid, A. (2013) NGS-assisted DNA-based digital qPCR facilitates stratification of CML patients in long-term molecular remission based on the presence of detectable BCR-ABL1 DNA. Blood, 122, Abstract 4006.
2. Bartley, P.A., Martin-Harris, M.H., Budgen, B.J., Ross, D.M. & Morley, A.A. (2010) Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia. British Journal of Haematology, 149, 231-236.
3. Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S.R., Morris, L.E., Holland, H.K., Mason, J.R., Alyea, E.P., Soiffer, R.J. & Ball, E.D. (2009) CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood, 113, 1581-1588.
4. Benjamini, O., Kantarjian, H., Rios, M.B., Jabbour, E., O'Brien, S., Jain, P., Cardenas-Turanzas, M., Faderl, S., Garcia-Manero, G., Ravandi, F., Borthakur, G., Quintas-Cardama, A. & Cortes, J. (2013) Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leukaemia & Lymphoma, doi: 10.3109/10428194.2013.831092.
5. Branford, S., Yeung, D.T., Prime, J.A., Choi, S.Y., Bang, J.H., Park, J.E., Kim, D.W., Ross, D.M. & Hughes, T.P. (2012) BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood, 119, 4264-4271.
6. Branford, S., Yeung, D.T., Ross, D.M., Prime, J.A., Field, C.R., Altamura, H.K., Yeoman, A.L., Georgievski, J., Jamison, B.A., Phillis, S., Sullivan, B., Briggs, N.E., Hertzberg, M., Seymour, J.F., Reynolds, J. & Hughes, T.P. (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood, 121, 3818-3824.
7. Burchert, A., Wolfl, S., Schmidt, M., Brendel, C., Denecke, B., Cai, D., Odyvanova, L., Lahaye, T., Muller, M.C., Berg, T., Gschaidmeier, H., Wittig, B., Hehlmann, R., Hochhaus, A. & Neubauer, A. (2003) Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood, 101, 259-264.
8. Burchert, A., Muller, M.C., Kostrewa, P., Erben, P., Bostel, T., Liebler, S., Hehlmann, R., Neubauer, A. & Hochhaus, A. (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. Journal of Clinical Oncology, 28, 1429-1435.
9. Chen, C.I., Maecker, H.T. & Lee, P.P. (2008) Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood, 111, 5342-5349.
10. Chen, C.I., Koschmieder, S., Kerstiens, L., Schemionek, M., Altvater, B., Pscherer, S., Gerss, J., Maecker, H.T., Berdel, W.E., Juergens, H., Lee, P.P. & Rossig, C. (2012) NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia, 26, 465-474.
11. Copland, M., Hamilton, A., Elrick, L.J., Baird, J.W., Allan, E.K., Jordanides, N., Barow, M., Mountford, J.C. & Holyoake, T.L. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107, 4532-4539.
12. Ding, J., Romani, J., Zaborski, M., Macleod, R.A., Nagel, S., Drexler, H.G. & Quentmeier, H. (2013) Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. PLoS ONE, 8, e83510.
13. Efficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., Deliliers, G.L., Barate, C., Rossi, A.R., Fioritoni, G., Luciano, L., Turri, D., Martino, B., Di Raimondo, F., Dabusti, M., Bergamaschi, M., Leoni, P., Simula, M.P., Levato, L., Ulisciani, S., Veneri, D., Sica, S., Rambaldi, A., Vignetti, M., Mandelli, F. & GIMEMA (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood, 118, 4554-4560.
14. Essers, M.A., Offner, S., Blanco-Bose, W.E., Waibler, Z., Kalinke, U., Duchosal, M.A. & Trumpp, A. (2009) IFNalpha activates dormant haematopoietic stem cells in vivo. Nature, 458, 904-908.
15. Flamant, S., Ritchie, W., Guilhot, J., Holst, J., Bonnet, M.L., Chomel, J.C., Guilhot, F., Turhan, A.G. & Rasko, J.E. (2010) Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica, 95, 1325-1333.
16. Goh, H.G., Lin, M., Fukushima, T., Saglio, G., Kim, D., Choi, S.Y., Kim, S.H., Lee, J., Lee, Y.S., Oh, S.M. & Kim, D.W. (2011) Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leukaemia & Lymphoma, 52, 896-904.
17. Goldman, J. & Gordon, M. (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leukaemia & Lymphoma, 47, 1-7.
18. Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., Abgrall, J.F. & Tanzer, J. (1997) Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. New England Journal of Medicine, 337, 223-229.
19. Iacobucci, I., Lonetti, A., Venturi, C., Ferrari, A., Papayannidis, C., Ottaviani, E., Abbenante, M.C., Paolini, S., Bresciani, P., Potenza, L., Parisi, S., Cattina, F., Soverini, S., Russo, D., Luppi, M. & Martinelli, G. (2014) Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leukemia Research, doi: 10.1016/j.leukres.2014.02.005.
20. Kanodia, S., Wieder, E., Lu, S., Talpaz, M., Alatrash, G., Clise-Dwyer, K. & Molldrem, J.J. (2010) PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS ONE, 5, e11770.
21. Kantarjian, H.M., Shah, N.P., Cortes, J.E., Baccarani, M., Agarwal, M.B., Undurraga, M.S., Wang, J., Ipina, J.J., Kim, D.W., Ogura, M., Pavlovsky, C., Junghanss, C., Milone, J.H., Nicolini, F.E., Robak, T., Van Droogenbroeck, J., Vellenga, E., Bradley-Garelik, M.B., Zhu, C. & Hochhaus, A. (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 119, 1123-1129.
22. Kumari, A., Brendel, C., Hochhaus, A., Neubauer, A. & Burchert, A. (2012) Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood, 119, 530-539.
23. Larson, R.A., Hochhaus, A., Hughes, T.P., Clark, R.E., Etienne, G., Kim, D.W., Flinn, I.W., Kurokawa, M., Moiraghi, B., Yu, R., Blakesley, R.E., Gallagher, N.J., Saglio, G. & Kantarjian, H.M. (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 26, 2197-2203.
24. Leber, B., Cervantes, F., Spector, N., Lipton, J.H., Etienne, G., Pasquini, R., Clementino, N.C., Guerci-Bresler, A., Forrest, D., Schwarer, A.P., Acharya, S., Collins, L., Szczudlo, T. & Hughes, T.P. (2013) Achievement and maintenance of deeper molecular response by switching to nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib: ENESTcmr 36-month follow-up. Blood (ASH Annual Meeting Abstracts), 120, 94.
25. Legros, L., Rousselot, P., Giraudier, S., Tulliez, M., Huguet, F., Nicolini, F.E. & Mahon, F.X. (2012) Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood, 120, 1959-1960.
26. Mahon, F.X., Delbrel, X., Cony-Makhoul, P., Faberes, C., Boiron, J.M., Barthe, C., Bilhou-Nabera, C., Pigneux, A., Marit, G. & Reiffers, J. (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. Journal of Clinical Oncology, 20, 214-220.
27. Mahon, F.X., Rea, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., Etienne, G., Reiffers, J. & Rousselot, P. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology, 11, 1029-1035.
28. Mahon, F.X., Nicolini, F.E., Noël, M.P., Escoffre, M., Charbonnier, A., Rea, D., Dubruille, V., Varet, B.R., Legros, L., Guerci, A., Etienne, G., Guilhot, F., Dulucq, S., Rousselot, P. & Guilhot, J. (2013) Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood (ASH Annual Meeting Abstracts), 122, 654.
29. Michor, F., Hughes, T.P., Iwasa, Y., Branford, S., Shah, N.P., Sawyers, C.L. & Nowak, M.A. (2005) Dynamics of chronic myeloid leukaemia. Nature, 435, 1267-1270.
30. Molldrem, J.J., Lee, P.P., Wang, C., Felio, K., Kantarjian, H.M., Champlin, R.E. & Davis, M.M. (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine, 6, 1018-1023.
31. Mori, S., Vagge, E., le Coutre, P., Abruzzese, E., Martino, B., Pungolino, E., Elena, C., Pierri, I., Assouline, S., D'Emilio, A., Gozzini, A., Giraldo, P., Stagno, F., Nagler, A., Iurlo, A., Rizzo, C., Fossati, A., Pogliani, E.M., Kim, D.W., Pirola, A., Piazza, R. & Gambacorti-Passerini, C. (2013) Validation of digital-PCR analysis through programmed imatinib interruption in Q-RT-PCR negative chronic myeloid leukemia patients. Blood (ASH Annual Meeting Abstracts), 122, 4040.
32. Mughal, T.I., Yong, A., Szydlo, R.M., Dazzi, F., Olavarria, E., van Rhee, F., Kaeda, J., Cross, N.C., Craddock, C., Kanfer, E., Apperley, J. & Goldman, J.M. (2001) Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. British Journal of Haematology, 115, 569-574.
33. Mumprecht, S., Schurch, C., Schwaller, J., Solenthaler, M. & Ochsenbein, A.F. (2009) Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood, 114, 1528-1536.
34. Norkin, M., Uberti, J.P. & Schiffer, C.A. (2011) Very late recurrences of leukemia: why does leukemia awake after many years of dormancy? Leukemia Research, 35, 139-144.
35. Ohyashiki, K., Katagiri, S., Tauchi, T., Ohyashiki, J.H., Maeda, Y., Matsumura, I. & Kyo, T. (2012) Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. British Journal of Haematology, 157, 254-256.
36. Preudhomme, C., Guilhot, J., Nicolini, F.E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., Rea, D., Jourdan, E., Allard, C., Delmer, A., Rousselot, P., Legros, L., Berger, M., Corm, S., Etienne, G., Roche-Lestienne, C., Eclache, V., Mahon, F.X. & Guilhot, F. (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. New England Journal of Medicine, 363, 2511-2521.
37. Radich, J.P., Gehly, G., Gooley, T., Bryant, E., Clift, R.A., Collins, S., Edmands, S., Kirk, J., Lee, A., Kessler, P., Schoch, G., Buckner, C.D., Sullivan, K.M., Appelbaum, F.R. & Thomas, E.D. (1995) Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood, 85, 2632-2638.
38. Rea, D., Rousselot, P., Guilhot, F., Tulliez, M., Nicolini, F., Guerci-Bresler, A., Legros, L., Gardembas, M., Giraudier, S., Guillerm, G. & Mahon, F. (2012) Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts. Blood (ASH Annual Meeting Abstracts), 120, 916.
39. Rea, D., Dulphy, N., Henry, G., Guilhot, J., Guilhot, F., Nicolini, F.E., Legros, L., Rousselot, P., Mahon, F.X. & Toubert, A. (2013) Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from immunostim, On Behalf Of STIM Investigators. Blood (ASH Annual Meeting Abstracts), 122, 856.
40. Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M.C. & Loeffler, M. (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nature Medicine, 12, 1181-1184.
41. Ross, D.M., Branford, S., Seymour, J.F., Schwarer, A.P., Arthur, C., Bartley, P.A., Slader, C., Field, C., Dang, P., Filshie, R.J., Mills, A.K., Grigg, A.P., Melo, J.V. & Hughes, T.P. (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia, 24, 1719-1724.
42. Ross, D.M., Bartley, P.A., Goyne, J., Morley, A.A., Seymour, J.F. & Grigg, A.P. (2011) Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica, 96, 1720-1722.
43. Ross, D.M., Branford, S., Seymour, J.F., Schwarer, A.P., Arthur, C., Yeung, D.T., Dang, P., Goyne, J.M., Slader, C., Filshie, R.J., Mills, A.K., Melo, J.V., White, D.L., Grigg, A.P. & Hughes, T.P. (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122, 515-522.
44. Rousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J.M., Maarek, O., Blanchet, O., Marit, G., Gluckman, E., Reiffers, J., Gardembas, M. & Mahon, F.X. (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood, 109, 58-60.
45. Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F.E., Varet, B., Gardembas, M., Etienne, G., Rea, D., Roy, L., Escoffre-Barbe, M., Guerci-Bresler, A., Tulliez, M., Prost, S., Spentchian, M., Cayuela, J.M., Reiffers, J., Chomel, J.C., Turhan, A., Guilhot, J., Guilhot, F. & Mahon, F.X. (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. Journal of Clinical Oncology, 32, 424-430.
46. Schmidt, M., Hochhaus, A., Nitsche, A., Hehlmann, R. & Neubauer, A. (2001) Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood, 97, 3648-3650.
47. Score, J., Calasanz, M.J., Ottman, O., Pane, F., Yeh, R.F., Sobrinho-Simoes, M.A., Kreil, S., Ward, D., Hidalgo-Curtis, C., Melo, J.V., Wiemels, J., Nadel, B., Cross, N.C. & Grand, F.H. (2010) Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia, 24, 1742-1750.
48. Sokal, J.E., Cox, E.B., Baccarani, M., Tura, S., Gomez, G.A., Robertson, J.E., Tso, C.Y., Braun, T.J., Clarkson, B.D., Cervantes, F., Rozman, C. and The Italian Cooperative CML Study Group. (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, 63, 789-799.
49. Takahashi, N., Kyo, T., Maeda, Y., Sugihara, T., Usuki, K., Kawaguchi, T., Usui, N., Okamoto, S., Ohe, Y., Ohtake, S., Kitamura, K., Yamamoto, M., Teshima, H., Motoji, T., Tamaki, T., Sawada, K. & Ohyashiki, K. (2012) Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica, 97, 903-906.
50. Tanaka, H., Imagawa, J., Okada, M., Nakamae, H., Hino, M., Murai, K., Ishida, Y., Kumagai, T., Sato, S., Ohashi, K., Sakamaki, H., Wakita, H., Uoshima, N., Nakagawa, Y., Minami, Y., Ogasawara, M., Takeoka, T., Akasaka, H., Morita, S., Sakamoto, J. & Kimura, S. (2013) Discontinuation of dasatinib in patients with CML who have maintained complete molecular response for at least one year: results from a prospective discontinuation (DADI) trial. Blood (ASH Annual Meeting Abstracts), 122, 3998.
51. Verma, D., Kantarjian, H., Jain, N. & Cortes, J. (2008) Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leukaemia & Lymphoma, 49, 1399-1402.
52. Warsch, W., Walz, C. & Sexl, V. (2013) JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood, 122, 2167-2175.
53. Yhim, H.Y., Lee, N.R., Song, E.K., Yim, C.Y., Jeon, S.Y., Shin, S., Kim, J.A., Kim, H.S., Cho, E.H. & Kwak, J.Y. (2012) Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leukemia Research, 36, 689-693.
54. Zhang, B., Irvine, D., Ho, Y.W., Buonamici, S., Manley, P., Holyoake, T.L., Copland, M. & Bhatia, R. (2010) Inhibition of chronic myeloid leukemia stem cells by the combination of the hedgehog pathway inhibitor LDE225 with nilotinib. Blood (ASH Annual Meeting Abstracts), 116, 514.